

Citation for published version:

Coates, LC, Tillett, W, Shaddick, G, Pincus, T, Kavanaugh, A & Helliwell, PS 2018, 'Value of the Routine Assessment of Patient Index Data 3 in Patients With Psoriatic Arthritis: Results From a Tight-Control Clinical Trial and an Observational Cohort', *Arthritis Care and Research*, vol. 70, no. 8, pp. 1198-1205.
<https://doi.org/10.1002/acr.23460>

DOI:

[10.1002/acr.23460](https://doi.org/10.1002/acr.23460)

Publication date:

2018

Document Version

Peer reviewed version

[Link to publication](#)

This is the pre-peer reviewed version of the following article: Coates, L. C., Tillett, W., Shaddick, G., Pincus, T., Kavanaugh, A. and Helliwell, P. S. (), Value of RAPID3 in patients with PsA: results from the TICOPA and LOPAS II databases. *Arthritis Care Res.*, which has been published in final form at <https://doi.org/10.1002/acr.23460>. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving

University of Bath

Alternative formats

If you require this document in an alternative format, please contact:
openaccess@bath.ac.uk

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Value of RAPID3 in patients with PsA: results from the TICOPA and LOPAS II databases

Laura C Coates, William Tillett, Gavin Shaddick, Theodore Pincus, Arthur Kavanaugh, Philip S Helliwell

Laura C Coates, MBChB, MRCP, PhD. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK and Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.

William Tillett MBChB, BSc, PhD, MRCP, Royal National Hospital for Rheumatic Diseases, Bath, UK, Department of Department of Pharmacy and Pharmacology, University of Bath, UK

Gavin Shaddick Department of Mathematics, University of Bath, Bath, UK

Theodore Pincus, Division of Rheumatology, Rush University School of Medicine, Chicago, IL 60606 USA

Arthur Kavanaugh Division of Rheumatology, Allergy, Immunology, University of California, San Diego School of Medicine, San Diego CA 92037 USA

Philip S Helliwell, MA, MD, FRCP. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK.

Funding statement – The TICOPA study was funded by Arthritis Research UK (grant number 18825). The research is also supported by the National Institute for Health Research (NIHR) Leeds Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. The research team acknowledges the support of the Comprehensive Clinical Research Network in supporting this research.

Corresponding author

Dr Philip S Helliwell

Leeds Institute of Rheumatic and Musculoskeletal Medicine

University of Leeds

2nd Floor, Chapel Allerton Hospital

Harehills Lane

Leeds, LS7 4SA

Tel - +44 113 392 3064

Fax - +44 113 392 4991

Email – p.helliwell@leeds.ac.uk

Word count – 2584, table count – 3, figure count - 3

Objective

RAPID3 is a patient reported, composite index, designed for feasibility in clinical care. RAPID3 was developed in rheumatoid arthritis, but has been found useful in many rheumatic diseases. We analysed RAPID3 in patients with psoriatic arthritis (PsA).

Methods

Post-hoc analyses were performed on two independent datasets, the tight control of PsA (TICOPA) trial, and the long-term outcome in PsA study (LOPAS II), an observational cohort. RAPID3 (0-30) is calculated as the total of three 0-10 scores for HAQ-DI (recalculated from 0-3), pain visual analog scale (VAS), and global VAS. Data were compared to the PsA disease activity score (PASDAS) and disease activity in psoriatic arthritis (DAPSA) and other available clinical measures, according to Spearman correlation coefficients, standardised response mean (SRM), standard error of the mean (SEM), smallest detectable difference (SDD), minimally important difference (MID in patients who improved) and receiver-operating characteristic (ROC) curves. RAPID3 remission was compared to criteria for both standard minimal disease activity (MDA) and very low disease activity (VLDA).

Results

RAPID3 was correlated significantly with PASDAS in TICOPA ($r=0.79$, $p<0.01$) and with DAPSA in LOPAS ($\rho=0.59$, $p<0.01$) and with most other measures in both datasets. RAPID3 discriminated between tight control and standard care in TICOPA at 48 weeks at levels comparable to DAPSA and the PASDAS ($p<0.01$). RAPID3 remission discriminated treatment groups in TICOPA intermediate between MDA and VLDA criteria.

Conclusion

RAPID3 appears comparably informative to PASDAS and DAPSA in PsA, with greater feasibility for routine clinical care.

Significance and Innovation

- RAPID3 correlates well with more comprehensive PsA-specific outcome measures, both those assessing arthritis (DAPSA) and global disease activity (PASDAS)
- RAPID3 can differentiate treatment groups in the TICOPA clinical trial.
- A modified RAPID3 including a skin VAS was not clearly superior in performance but levels of skin disease were low in the datasets used.
- RAPID3 remission correlates well at the individual patient level with other remission measures but physical examination is still required for optimal clinical decision making.

Psoriatic arthritis (PsA) is a complex disease involving both the musculoskeletal and cutaneous systems. Many outcome measures have been developed specifically for PsA to reflect both systems, with composite indices, which may include assessment of arthritis (both peripheral and axial), enthesitis, dactylitis, skin and nail psoriasis, and patient-reported outcomes (1). Such composite indices are used widely in clinical trials, but generally not incorporated into routine practice due to their complexity(1). The only quantitative data available in routine care of many PsA (and other rheumatology) patients are laboratory tests, with significant limitations.

Routine assessment of patient index data 3 (RAPID3) is an index composed of only the 3 patient self-reported measures from the rheumatoid arthritis (RA) Core Data Set(2): physical function on a health assessment questionnaire (HAQ) or its multidimensional version (MDHAQ), and pain and patient global estimate on two 0-10 visual analogue scales (VAS) (3). RAPID3 was developed initially in RA, but subsequently has been found informative in axial spondyloarthritis(4-7), osteoarthritis(8), gout(9) systemic lupus erythematosus(10) and other arthritides(9, 11-13). Whilst the primary goal for RAPID3 was feasibility in routine care to provide quantitative data for prognosis, management and outcomes, scores generally have been found quite comparable to more elaborate disease-specific indices (14).

This study assessed the potential value of RAPID3 to depict clinical status compared to PASDAS, DAPSA, and other measures in two datasets, the tight control of PsA (TICOPA) study,

a clinical trial, and the long term outcome of PsA study (LOPAS II), an observational cohort. An important consideration that RAPID3 may not address the dermatological aspects of PsA effectively was analysed using a modified RAPID3Ps, which included a fourth item, a VAS scale for skin disease activity that could be added to the original RAPID3.

Materials and Methods

Data. Post-hoc analyses were performed on two independent datasets to study the value of RAPID3 in PsA. First, we analysed data from the tight control of PsA (TICOPA) clinical trial (ClinicalTrials.gov NCT01106079, ISRCTN30147736), to assess its performance in a controlled trial setting. Second, we used data from the long-term outcomes in PsA study (LOPAS II) to assess its performance in an observational cohort setting (15).

TICOPA trial. The TICOPA trial is a UK multicentre randomised controlled trial, in which 206 adults with early psoriatic arthritis were randomly assigned on a 1:1 ratio either to tight control with a step-up regimen aiming for minimal disease activity using methotrexate, combination disease-modifying anti-rheumatic drugs (DMARDs) and anti-tumour necrosis factor drugs as required or to standard care(16). In the TICOPA dataset, the PsA disease activity score (PASDAS) was used as the gold standard comparator, as this composite measure addresses all aspects of psoriatic disease(17). Differences between treatment groups according to RAPID3, PASDAS and other PsA measures were compared.

LOPAS II observational cohort. LOPAS II is a prospective, multicentre observational cohort study to investigate the effect of conventional synthetic disease modifying anti rheumatic drugs (csDMARD) and anti-Tumour Necrosis Factor inhibitors (anti-TNF) on clinical and patient reported outcomes among PsA patients of any age and disease duration who fulfilled the classification for psoriatic arthritis (CASPAR) criteria(18) and were being commenced on

csDMARD or anti-TNF as part of routine clinical care. In the LOPAS study, analyses were undertaken on participants with complete data at baseline and three months follow up. The Disease Activity in Psoriatic Arthritis (DAPSA) was used as a composite measure of articular disease (calculated from the 66/ 68 tender and swollen joints count, c reactive protein, patient global assessment and pain visual analogue scales)(19). The required items for MDA and PASDAS were not all available in this dataset.

RAPID3 index. RAPID3 scores are calculated as the 0-30 sum of the three 0-10 RA core data set measures of physical function, pain, and a patient global estimate (3). Physical function is assessed on a Health Assessment Questionnaire (HAQ) (20) or multidimensional version (MDHAQ); activities are scored 0-3 and the total of 0-30 or mean 0-3, are converted to a 0-10 score. Pain and a patient global estimate were scored in these studies on a (0 -10) visual analog scale (VAS) using the GRAPPA PsA global wording “In all the ways in which your psoriasis and arthritis, as a whole, affects you...”. In addition, a modified RAPID3 which included a VAS scale for skin disease activity as a fourth item was studied, because of consideration that the 3-item RAPID3 would not be informative concerning the dermatological aspects of PsA.

The range for RAPID3 is 0-30 and severity categories have been defined for RA: ≤ 3 for remission, 3.1-6.0 for low, 6.1-12.0 for moderate, and >12 for high severity (21). These potential categories were studied in comparison with other remission and low disease categories from PsA specific measures, at both group and individual levels. RAPID3 remission was compared to both the standard Minimal Disease Activity (MDA) criteria(22) and the very low disease activity (VLDA) criteria(23), which were developed specifically for

PsA and have been shown to correlate well with other disease activity measures(24, 25) in PsA. MDA also is associated with physician and patient opinion of low disease activity using anchor questions(23), and has prognostic value for better functional outcome and lower rates of radiographic damage(26). The MDA criteria for PsA require meeting 5 of 7 cutpoints in 7 measures: HAQ \leq 0.5, patient global VAS \leq 20mm, patient pain VAS \leq 15mm (the three RAPID measures, though at different cut-points); tender joint count (TJC) \leq 1; swollen joint count (SJC) \leq 1; enthesitis count \leq 1 and psoriasis area and severity index (PASI) \leq 1 or body surface area (BSA) \leq 3(22). To meet VLDA criteria, all seven cut points must be met(23). This endpoint has been investigated in view of the emphasis on remission as the ideal target for treatment(27); preliminary validation has indicated that it is a very stringent measure(23). A more stringent method to assess remission based on RAPID3, with addition of whether a patient has 0 or 1 vs >1 swollen joint (RAPID3SJC1)(28, 29) also was analysed

In studies of LOPAS II data, construct validity was assessed using Spearman correlation coefficients with other disease outcome measures. Agreement between the DAPSA and RAPID3 was determined on the Bland Altman plot(30) (after rescaling both measures to allow comparison on the same plot). Responsiveness was assessed using Standard Error of the Mean (SEM), Standardised Response Mean (SRM) and Smallest Detectable Difference (SDD). The Minimally Important Difference (MID) was determined using the health based anchor method (mean change in score amongst patients who improved) and Receiver Operator Characteristic Curve (ROC) methods (the change in score at the top left corner of the curve representing the smallest amount of misclassification). Responsiveness of the

measures as continuous variables and their correlations with other disease activity measures were assessed in both cohorts

Results

TICOPA clinical trial. In the TICOPA study, the disease duration of patients was less than 24 months and their mean age was 44 years. RAPID3 scores were correlated significantly with PASDAS (Spearman's correlation 0.80, $p < 0.01$) at all baseline and follow up visits (figure 1), indicating construct validity. RAPID3Ps (which includes a skin VAS) was also correlated highly with PASDAS at similar levels. The change in score at follow up was also correlated significantly with the change in PASDAS (0.64, $p < 0.01$).

RAPID3 was highly discriminant of change in the tight control vs standard treatment groups (Table 1). (t value -3.43, $p < 0.01$) and superior to each individual measure. Patient-reported measures were more discriminant than joint counts (Table 1). RAPID3 also was similar in discrimination to the disease activity in PsA (DAPSA) score, but slightly less than PASDAS (table 2). When plotting mean scores for both PASDAS and RAPID3 in the TICOPA trial, similar responses are seen at each timepoint (figure S1).

The proportions of patients who were classified as in remission according to RAPID3 and RAPID3SJC1 lies between MDA and VLDA (table 2), as might be expected. RAPID3 NR and RAPID3SJC1 in TICOPA also were highly discriminant between treatment groups (table 2), although slightly lower than MDA and DAPSA remission. At an individual (rather than group) level, exact agreement between MDA and RAPID3 remission was seen in 85.2% of patients at 48 weeks. Only five patients (of 67) in RAPID3 remission were not in MDA due to higher physician assessed disease activity. By contrast, 22 patients were in MDA but did not meet

the RAPID3 remission levels due to high patient reported measures. The majority of patients (58 of 67) in RAPID3 remission also met the more stringent RAPID3SJC1 criteria (RAPID3 remission + $SJC \leq 1$) (28, 29).

Agreement between RAPID3 remission and VLDA was slightly lower than MDA (percentage exact agreement (PEA) of 73.6%). Compared to this more stringent target, 44 of the 67 patients in RAPID3 remission were not in VLDA whilst only four patients were in VLDA but did not meet RAPID3 NR due to high patient reported measures. This finding suggests that the RAPID3 remission cut off lies between MDA and VLDA in terms of disease activity cut off. For those in RAPID3 remission, the levels of residual disease activity is shown in table S1. The majority of patients have low levels of ongoing active disease including CRP which is normal in around 75% of patients.

LOPAS observational study. In the LOPAS study, the mean disease duration 5.8 years (sd 7.77) and the mean age was 51 years. RAPID3 scores correlated significantly with the DAPSA composite measure (Spearman correlation coefficient 0.59, $p < 0.01$) as confirmed in figure 2, and with other patient reported outcomes: Joint VAS (0.83), EQ5D (0.65), FACIT fatigue (0.63). Correlation with clinical joint count and CRP was lower: tender joint count (0.39), swollen joint count (0.21), CRP (0.17). No significant difference was seen between the response to treatment (within each independent treatment group) according to RAPID3 or DAPSA for either the TNF ($p = 0.76$) or DMARD ($p = 0.09$) groups (Figure S1).

RAPID3 was responsive according to the mean change, SEM, SRM and SDD during follow up (Table 3). The MID for improvement using the anchor method for the RAPID3 was -8.1 (sd 5.9) and DAPSA -27.9 (sd 23.7). The MID using the ROC method (figure 3) for the RAPID3 was -5.1 (AUC 0.84) and DAPSA -16.7 (AUC 0.75). Using initiation of treatment (baseline visit) as a gold standard for active disease, only a small number of patients were potentially misclassified as being in remission or low disease activity by either score: DAPSA (2.3%) and RAPID3 (5%). RAPID3 was correlated significantly with the EQ5D, Joint VAS and FACIT fatigue, but at lower levels with clinical joint counts and the CRP. This finding highlights some disconnect between physician and patient reported outcomes.

Discussion

These analyses indicate that RAPID3 and RAPID3Ps show good responsiveness and discrimination in PsA. In the TICOPA dataset, RAPID3 is correlated highly with the PASDAS score and is more discriminative than individual measures and the DAPSA score. In the LOPAS dataset, RAPID3 is correlated significantly with the DAPSA and had similar responsiveness. We also report an estimate of the MID for improvement and smallest detectable difference for the RAPID3 in PsA.

The RAPID3 score is a generic tool developed to assess patient status quantitatively in clinical practice. It was developed in RA and has been found of value in many rheumatic conditions, including spondyloarthritis(4-7), osteoarthritis(8), gout(9) systemic lupus erythematosus(10) and other arthritides(9, 11-13). However, in PsA, in addition to the musculoskeletal

manifestations, most patients also have skin psoriasis. In these analyses, adding a skin disease activity VAS to create the RAPID3Ps did not show a meaningful advantage over the established RAPID3 score. This may be anticipated since RAPID3 measures constitute 3 of 4 in RAPID3Ps, skin involvement was mild in these cohorts and it may be captured at least in part in the patient global assessment.

RAPID3 NR also performed well with the vast majority of patients who were identified as being in remission showing low levels of residual disease activity. The RAPID3 measure includes the same 3 patient reported outcomes as the MDA criteria, and cut points for the patient reported items of MDA are similar to RAPID3 remission. Since MDA requires 5 of 7 cut points, 2 patient measures may be above the cut point, explaining why RAPID3 remission appears intermediate between MDA and VLDA in stringency. Only a few cases were in RAPID3 remission but had active disease as assessed by the physician using joint counts and skin scores. Nonetheless, all measures and indices are only a guide, and a clinical assessment is required for optimal clinical decisions.

The use of the HAQ as a measure of disease activity in PsA may be questioned. The HAQ primarily assesses upper limb (hand) function and was developed in RA. PsA has different musculoskeletal manifestations (enthesitis/ dactylitis, differing joint distributions such as large joint monoarthritis). Furthermore it has been suggested that HAQ function scores become more influenced by damage than activity in established disease, potentially limiting responsiveness(31). However, despite these theoretical concerns we found RAPID3 to be sensitive to change and discriminative in early disease (TICOPA) and later disease (LOPAS), in

keeping with other studies showing responsiveness of HAQ even in established disease(32, 33).

Several methodological limitations are recognized in interpreting the finding of this study. The RAPID3 was calculated from existing outcome measures collected within the two studies. Therefore the HAQ-DI was used instead of the MD-HAQ and VAS scales for pain and global disease activity were used rather than the NRS in the RAPID3 tool. We believe from previous studies that these are comparable but future research with the specific RAPID3 tool is required. To maximise feasibility in clinical practice, the use of a standard tool (RAPID3) across all diseases appears desirable. However, it must be noted that these patients were all recruited from rheumatology clinics and the average levels of skin disease were very low (TICOPA: median PASI 2.6, LOPAS II: median Dermatology Quality of Life Index – DLQI 2.0 and skin VAS 30.5/100). The absence of a skin specific measure may limit performance in a population with substantial skin disease. There were also a few patients in RAPID3 remission who had signs of active disease on clinical assessment. Thus, clinical assessment, in addition to the RAPID3 or any index, is required in all patients. Unfortunately there was little change in radiographic damage over the 48 week period of the TICOPA study and radiographs were not routinely performed in the LOPAS study therefore the relationship between RAPID3 and radiographic damage has not been explored in this paper.

We have not analysed possible influence of contextual factors or comorbidities on RAPID3. Such contextual factors as fibromyalgia are known to impact all rheumatology indices, which necessarily include at least one patient-reported measure independent of disease activity.

For example, a patient who has no swollen joints and a CRP of 10mg/L, but 14 tender joints and a patient global assessment of 8 would have a DAPSA of 23 even if the physician global assessment were “0”; the RAPID3 would be 16, assuming a pain score of 8, and both indices would indicate “high activity/severity.” Similar considerations pertain to most rheumatology indices, as concomitant fibromyalgia was found to be associated with higher scores by Brikman *et al* in all in composite measures including the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the Dermatology Life Quality Index, Leeds Enthesitis Index (LEI). Composite Psoriatic Disease Activity Index (CPDAI), MDA and DAPSA scores(34). We emphasize again that all indices, whether RAPID3, PASDAS, DAPSA or others, must be informed by accompanying clinical, serological and imaging assessments in clinical practice. Whilst such measures should be viewed as providing valuable quantitative data which add to a standard medical history and physical examination toward optimal clinical decisions, an index should not be the only basis for a clinical decision other than in a protocol-directed research study. A final limitation is that we have not assessed the stability (test re-test reliability) of the RAPID 3 in this study, although one would anticipate reliability similar to that established in other diseases (21, 35).

We report data from two independent datasets examining the responsiveness and discrimination of RAPID3 in PsA. We also report data suggesting the addition of a skin assessment does not improve sensitivity to change in these particular cohorts. We also report an estimate of the MID for improvement in PsA. Taken together these data support the value and validity of RAPID3 as a feasible and sensitive measure of disease activity in PsA.

References

1. Coates LC, Helliwell PS. Treating to target in psoriatic arthritis: how to implement in clinical practice. *Ann Rheum Dis*. 2016;75(4):640-3.
2. Boers M, Tugwell P, Felson DT, van Riel PL, Kirwan JR, Edmonds JP, et al. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. *J Rheumatol Suppl*. 1994;41:86-9.
3. Pincus T, Yazici Y, Bergman MJ. RAPID3, an index to assess and monitor patients with rheumatoid arthritis, without formal joint counts: similar results to DAS28 and CDAI in clinical trials and clinical care. *Rheumatic diseases clinics of North America*. 2009;35(4):773-8, viii.
4. Park SH, Choe JY, Kim SK, Lee H, Castrejon I, Pincus T. Routine Assessment of Patient Index Data (RAPID3) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Scores Yield Similar Information in 85 Korean Patients With Ankylosing Spondylitis Seen in Usual Clinical Care. *J Clin Rheumatol*. 2015;21(6):300-4.
5. Danve A, Reddy A, Vakil-Gilani K, Garg N, Dinno A, Deodhar A. Routine Assessment of Patient Index Data 3 score (RAPID3) correlates well with Bath Ankylosing Spondylitis Disease Activity index (BASDAI) in the assessment of disease activity and monitoring progression of axial spondyloarthritis. *Clinical rheumatology*. 2015;34(1):117-24.
6. Cinar M, Yilmaz S, Cinar FI, Koca SS, Erdem H, Pay S, et al. A patient-reported outcome measures-based composite index (RAPID3) for the assessment of disease activity in ankylosing spondylitis. *Rheumatology international*. 2015;35(9):1575-80.

7. Castrejon I, Pincus T, Wendling D, Dougados M. Responsiveness of a simple RAPID-3-like index compared to disease-specific BASDAI and ASDAS indices in patients with axial spondyloarthritis. *RMD Open*. 2016;2(2):e000235.
8. Holt RJ, Fort JG, Grahn AY, Kent JD, Bello AE. Onset and durability of pain relief in knee osteoarthritis: Pooled results from two placebo trials of naproxen/esomeprazole combination and celecoxib. *Phys Sportsmed*. 2015;43(3):200-12.
9. Castrejon I, Bergman MJ, Pincus T. MDHAQ/RAPID3 to recognize improvement over 2 months in usual care of patients with osteoarthritis, systemic lupus erythematosus, spondyloarthropathy, and gout, as well as rheumatoid arthritis. *J Clin Rheumatol*. 2013;19(4):169-74.
10. Askanase AD, Castrejon I, Pincus T. Quantitative data for care of patients with systemic lupus erythematosus in usual clinical settings: a patient Multidimensional Health Assessment Questionnaire and physician estimate of noninflammatory symptoms. *J Rheumatol*. 2011;38(7):1309-16.
11. Pincus T, Askanase AD, Swearingen CJ. A multi-dimensional health assessment questionnaire (MDHAQ) and routine assessment of patient index data (RAPID3) scores are informative in patients with all rheumatic diseases. *Rheumatic diseases clinics of North America*. 2009;35(4):819-27, x.
12. Michelsen B, Fiane R, Diamantopoulos AP, Soldal DM, Hansen IJ, Sokka T, et al. A comparison of disease burden in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. *PLoS One*. 2015;10(4):e0123582.
13. Annapureddy N, Elsallabi O, Baker J, Sreih AG. Patient-reported outcomes in ANCA-associated vasculitis. A comparison between Birmingham Vasculitis Activity Score and routine assessment of patient index data 3. *Clinical rheumatology*. 2016;35(2):395-400.

14. Pincus T, Yazici Y, Castrejon I. Pragmatic and scientific advantages of MDHAQ/RAPID3 completion by all patients at all visits in routine clinical care. *Bull NYU Hosp Jt Dis.* 2012;70 Suppl 1:30-6.
15. Tillett W, Shaddick G, Askari A, Cooper A, Creamer P, Clunie G, et al. Factors influencing work disability in psoriatic arthritis: first results from a large UK multicentre study. *Rheumatology (Oxford).* 2015;54(1):157-62.
16. Coates LC, Moverley AR, McParland L, Brown S, Navarro-Coy N, O'Dwyer JL, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. *Lancet.* 2015;386(10012):2489-98.
17. Helliwell PS, Fitzgerald O, Fransen J, Gladman DD, Kreuger GG, Callis-Duffin K, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). *Ann Rheum Dis.* 2012(online first 17/07/2012).
18. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. *Arthritis Rheum.* 2006;54(8):2665-73.
19. Schoels M, Aletaha D, Funovits J, Kavanaugh A, Baker D, Smolen JS. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. *Ann Rheum Dis.* 2010;69(8):1441-7.
20. Pincus T, Summey JA, Soraci SA, Jr., Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. *Arthritis Rheum.* 1983;26(11):1346-53.
21. Pincus T, Swearingen CJ, Bergman M, Yazici Y. RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine

care: proposed severity categories compared to disease activity score and clinical disease activity index categories. *J Rheumatol*. 2008;35(11):2136-47.

22. Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. *Ann Rheum Dis*. 2010;69(1):48-53.
23. Coates LC, Helliwell PS. Defining Low Disease Activity States in Psoriatic Arthritis using Novel Composite Disease Instruments. *J Rheumatol*. 2016;43(2):371-5.
24. Coates LC, Cook R, Lee KA, Chandran V, Gladman DD. Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. *Arthritis Care Res (Hoboken)*. 2010;62(7):970-6.
25. Coates LC, Helliwell PS. Validation of minimal disease activity for psoriatic arthritis using interventional trial data. *Arthritis Care and Research*. 2010;62(2):965-69.
26. Kavanaugh A, van der Heijde D, Beutler A, Gladman D, Mease P, Krueger GG, et al. Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled Study. *Arthritis Care Res (Hoboken)*. 2016;68(2):267-74.
27. Smolen JS, Braun J, Dougados M, Emery P, Fitzgerald O, Helliwell P, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. *Ann Rheum Dis*. 2014;73(1):6-16.
28. Castrejon I, Dougados M, Combe B, Guillemin F, Fautrel B, Pincus T. Can remission in rheumatoid arthritis be assessed without laboratory tests or a formal joint count? possible remission criteria based on a self-report RAPID3 score and careful joint examination in the ESPOIR cohort. *J Rheumatol*. 2013;40(4):386-93.
29. Castrejon I, Dougados M, Combe B, Fautrel B, Guillemin F, Pincus T. Prediction of Remission in a French Early Arthritis Cohort by RAPID3 and other Core Data Set Measures,

but Not by the Absence of Rheumatoid Factor, Anticitrullinated Protein Antibodies, or Radiographic Erosions. *J Rheumatol.* 2016;43(7):1285-91.

30. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. *Lancet.* 1986;1(8476):307-10.

31. Husted JA, Tom BD, Farewell VT, Schentag CT, Gladman DD. A longitudinal study of the effect of disease activity and clinical damage on physical function over the course of psoriatic arthritis: Does the effect change over time? *Arthritis Rheum.* 2007;56(3):840-9.

32. Pincus T, Amara I, Segurado OG, Bergman M, Koch GG. Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials. *J Rheumatol.* 2008;35(2):201-5.

33. Pincus T, Richardson B, Strand V, Bergman MJ. Relative efficiencies of the 7 rheumatoid arthritis Core Data Set measures to distinguish active from control treatments in 9 comparisons from clinical trials of 5 agents. *Clinical and experimental rheumatology.* 2014;32(5 Suppl 85):S-47-54.

34. Brikman S, Furer V, Wollman J, Borok S, Matz H, Polachek A, et al. The Effect of the Presence of Fibromyalgia on Common Clinical Disease Activity Indices in Patients with Psoriatic Arthritis: A Cross-sectional Study. *J Rheumatol.* 2016;43(9):1749-54.

35. Uhlig T, Kvien TK, Pincus T. Test-retest reliability of disease activity core set measures and indices in rheumatoid arthritis. *Ann Rheum Dis.* 2009;68(6):972-5.

Table 1: Responsiveness of individual items and indices, ranked by t value in the TICOPA trial

Measure	Tight Control				Standard Care				T	p
	Baseline	Mean change	SRM	ES	Baseline	Mean change	SRM	ES		
PASDAS	5.27	-2.49	-1.45	-1.77	4.96	-1.38	-0.83	-1.09	-3.75	0.00
RAPID3	4.18	-2.16	-1.07	-1.06	3.59	-1.01	-0.47	-0.52	-3.43	0.00
Phys Global	44.10	-32.26	-1.57	-1.62	40.80	-19.83	-0.86	-1.27	-3.34	0.00
Pt Global	56.15	-33.60	-1.05	-1.20	51.54	-18.64	-0.56	-0.69	-3.12	0.00
pain VAS	53.42	-31.92	-1.05	-1.18	47.33	-17.79	-0.56	-0.68	-2.82	0.01
DAPSA	31.24	-19.01	-1.08	-0.94	30.04	-11.45	-0.69	-0.53	-2.61	0.01
Fatigue VAS	48.85	-21.44	-0.73	-0.78	46.39	-13.20	-0.46	-0.46	-1.84	0.07
TJC	12.33	-6.62	-0.65	-0.56	13.22	-3.34	-0.28	-0.24	-1.57	0.12
SJC	7.57	-6.27	-0.96	-0.97	6.82	-4.50	-0.57	-0.58	-1.22	0.22

DAPSA – disease activity in psoriatic arthritis, ES – effect size, PASDAS - PsA disease activity score, Phys – physician, Pt – patient, RAPID3 – routine assessment of patient index data 3, TJC – tender joint count, SJC – swollen joint count, SRM – standardised response mean, VAS – visual analogue score

Table 2: Discriminative capacity of disease activity state definitions in the TICOPA trial

Measure	TC % achieved	StdC % achieved	Chi Squared	P value
MDA	58.4	34.1	10.106	0.001
VLDA	22.5	7.3	7.603	0.006
RAPID3 near remission	44.3	25.3	7.483	0.006
RAPID3Ps near remission	75.3	63.7	2.950	0.112
RAPID3SJC1	42.2	22.9	7.303	0.009
RAPID3 near remission or mild	58.8	45.1	3.535	0.060
PASDAS low	63.9	50.5	3.432	0.064
DAPSA low (Helliwell)	76.7	65.9	2.463	0.117
DAPSA low (JS)	70.0	58.5	2.464	0.117
DAPSA remission (JS)	43.3	19.5	11.193	0.001

DAPSA – disease activity in psoriatic arthritis, MDA – minimal disease activity, RAPID3 – routine assessment of patient index data 3, PASDAS – psoriatic arthritis disease activity score, StdC – standard care, TC – tight control, TICOPA – tight control of psoriatic arthritis, VLDA – very low disease activity

Table 3 - LOPAS II Sensitivity to change of the RAPID3 with other disease outcomes

Outcome	Mean change (sd)	SEM	SRM	SDD
RAPID3	-6.2 (9.9)	6.15	0.62	8.5
DAPSA	-18.4 (30.0)	17.6	0.61	40.8
HAQ	-0.20 (0.52)	0.29	0.38	0.4
EQ5D VAS	9.0 (24.6)	13.8	0.37	19.2
FACIT-Fatigue	4.4 (9.3)	5.6	0.45	7.7
Global VAS	-18.8 (31.7)	19.5	0.59	27.1
Pain VAS	-17.2 (30.1)	18.5	0.57	25.6
Joint VAS	-17.2 (31.4)	18.0	0.54	24.9
Skin VAS	-11.2 (31.1)	17.5	0.36	24.2

Figure 1 - Correlation between PASDAS and RAPID3 and RAPID3Ps scores at all key visits in TICOPA (Spearman's rho 0.80, $p < 0.01$ and 0.82, $p < 0.01$)

Figure 2 - Bland Altman Plot of DAPSA/ RAPID3 in LOPAS2 dataset

Figure 3 - Receiver Operator Curves of DAPSA and RAPID 3 in the LOPAS dataset